抗精神病薬市場：クラス別、適応症別-2025～2030年の世界予測

抗精神病薬市場は、2023年に96億5,000万米ドルと評価され、2024年には104億2,000万米ドルに達すると予測され、CAGR 8.01％で成長し、2030年には165億6,000万米ドルに達すると予測されています。

抗精神病薬市場には、主に統合失調症や双極性障害などの精神病関連疾患の管理に使用される医薬品が含まれます。この市場の範囲は、重度のうつ病や不安障害の治療を含む、多様なメンタルヘルス用途にまで広がっています。これらの薬剤の必要性は、精神疾患の発生率の上昇と、世界の認知度と診断率の拡大によって裏付けられています。主要最終用途セグメントには病院、クリニック、リハビリセンターなどがあり、これらの施設では患者の心理状態を安定させ、生活の質を高めるためにこれらの薬剤を利用しています。この市場の主要成長要因としては、メンタルヘルス疾患の有病率の増加、薬剤製剤の進歩、メンタルヘルス支援施策などが挙げられます。副作用が少なく、有効性プロファイルが強化された次世代の抗精神病薬を開発する機会は豊富にあります。精神疾患の遺伝的・生物学的基盤に焦点を当てた調査への投資は、個別化された薬剤療法戦略につながる可能性があり、企業にとってイノベーションを起こす有利な機会となります。薬理学的治療と組み合わせたデジタル治療も、特に技術が医療提供に統合されるにつれて、潜在的な成長セグメントとなります。しかし、市場開拓に影響を及ぼす限界として、医薬品開発にかかるコストの高さ、規制要件の厳しさ、精神疾患にまつわるスティグマ（烙印）が挙げられ、これらは市場拡大の妨げとなる可能性があります。体重増加や代謝の問題など、既存の抗精神病薬に関連する副作用などの課題は、患者が配合された治療レジメを遵守することを妨げる可能性があります。このような限界を克服するために、製薬会社は徐放性製剤や経皮吸収パッチなどの新規ドラッグデリバリーシステムによる副作用の軽減に注力する可能性があります。全体として、個別化医療の革新、創薬のための人工知能の活用、包括的なメンタルヘルスサービスの統合は、事業の大幅な成長を促進し、治療状況を一変させる可能性があり、抗精神病薬市場の現在進行中の複雑でありながら有望な性質を浮き彫りにしています。

市場力学：急速に進化する抗精神病薬市場の主要市場洞察を公開

抗精神病薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 精神病と関連疾患の有病率の増加
  • 政府による医薬品認可の増加
  • メンタルヘルスとウェルネスに関する意識の高まり
• 市場抑制要因
  • 既存ブランドの特許切れ
• 市場機会
  • 新規抗精神病薬の研究開発と臨床検査
  • 抗精神病薬検査の改善
• 市場課題
  • 厳しい規制の枠組みとコンプライアンス

ポーターのファイブフォース：抗精神病薬市場をナビゲートする戦略ツール

ポーターのファイブフォース：」フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗精神病薬市場における外部からの影響の把握

外部マクロ環境要因は、抗精神病薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：抗精神病薬市場における競合情勢の把握

抗精神病薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：抗精神病薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗精神病薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：抗精神病薬市場における成功への道筋を描く

抗精神病薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 精神病と関連疾患の罹患率の増加
    • 政府による医薬品承認の増加
    • メンタルヘルスとウェルネスに関する意識の高まり
  • 抑制要因
    • 既存ブランドの特許切れ
  • 機会
    • 新しい抗精神病薬の研究開発と臨床検査
    • 抗精神病薬の検査の改善
  • 課題
    • 厳格な規制枠組みとコンプライアンス
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗精神病薬市場：クラス別

• イントロダクション
• 第一世代
  • ハルド
  • ナヴァネ
• 第二世代
  • ジオドン
  • インヴェガ
  • ラトゥーダ
  • リスパダール
  • セロクエル
  • ジプレキサ
• 第三世代
  • エビリファイ

第7章 抗精神病薬市場：適応症別

• イントロダクション
• 双極性障害
• 痴呆
• 統合失調症
• 単極性うつ病

第8章 南北アメリカの抗精神病薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の抗精神病薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの抗精神病薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Alkermes, Inc.
• AMBOSS GmbH
• Amgen Inc
• Arlak BIoTech
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Dr. Reddy's Laboratories, Ltd.
• Eli Lilly and Company
• Flagship BIoTech International Pvt. Ltd.
• GlaxoSmithKline PLC
• H. Lundbeck A/S
• Johnson & Johnson Services Inc.
• Lifecare Neuro Products Ltd.
• Luye Pharma Group
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co. Ltd.
• Pfizer, Inc.
• S. Karger AG
• Seqirus Pty Ltd
• Sumitomo Dainippon Pharma Co., Ltd.
• Teva Pharmaceutical Industries, Ltd.
• Vanda Pharmaceuticals Inc.

LIST OF FIGURES

• FIGURE 1. ANTIPSYCHOTIC DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIPSYCHOTIC DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALDO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY NAVANE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GEODON, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INVEGA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LATUDA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERDAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SEROQUEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ZYPREXA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ABILIFY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY UNIPOLAR DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 73. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 75. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 78. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 80. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 164. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 166. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 184. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 186. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 189. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 191. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Antipsychotic Drugs Market was valued at USD 9.65 billion in 2023, expected to reach USD 10.42 billion in 2024, and is projected to grow at a CAGR of 8.01%, to USD 16.56 billion by 2030.

The antipsychotic drugs market encompasses medications primarily used to manage psychosis-related conditions such as schizophrenia and bipolar disorder. This market's scope extends to diverse mental health applications, including the treatment of severe depression and anxiety disorders. The necessity for these drugs is underscored by the rising incidence of mental health disorders and the expansion of awareness and diagnosis rates worldwide. The primary end-use sectors include hospitals, clinics, and rehabilitation centers, which utilize these medications to stabilize patients' psychological states and enhance their quality of life. Key growth factors for this market include the increasing prevalence of mental health conditions, advancements in drug formulations, and supportive mental health policies. Opportunities abound in developing next-generation antipsychotic drugs with fewer side effects and enhanced efficacy profiles. Investments in research focused on the genetic and biological underpinnings of psychiatric disorders could lead to personalized medication strategies, presenting a lucrative opportunity for businesses to innovate. Digital therapeutics, combined with pharmacological treatments, also represent a potential area for growth, especially as technology integrates into healthcare delivery. However, limitations affecting market growth include the high cost of drug development, stringent regulatory requirements, and the stigma associated with mental health disorders, which may hinder market expansion. Challenges such as side effects associated with existing antipsychotic drugs, including weight gain and metabolic issues, can deter patients from adherence to prescribed treatment regimes. To overcome these limitations, pharmaceutical companies might focus on reducing adverse effects through novel drug delivery systems, such as sustained-release formulations or transdermal patches. Overall, innovation in personalized medicine, leveraging artificial intelligence for drug discovery, and integrating comprehensive mental health services could drive significant business growth and transform the treatment landscape, highlighting the ongoing complex yet promising nature of the antipsychotic drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antipsychotic Drugs Market

The Antipsychotic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of psychosis and associated diseases
  • Rising drug approval from governments
  • Growing awareness regarding mental health and wellness
• Market Restraints
  • Patent expiry of established brands
• Market Opportunities
  • R&D and clinical trials for new antipsychotic drugs
  • Improvements in antipsychotic drug testing
• Market Challenges
  • Stringent regulatory framework and compliance

Porter's Five Forces: A Strategic Tool for Navigating the Antipsychotic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antipsychotic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antipsychotic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antipsychotic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antipsychotic Drugs Market

A detailed market share analysis in the Antipsychotic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antipsychotic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antipsychotic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antipsychotic Drugs Market

A strategic analysis of the Antipsychotic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antipsychotic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes, Inc., AMBOSS GmbH, Amgen Inc, Arlak Biotech, AstraZeneca PLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Company, Flagship Biotech International Pvt. Ltd., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services Inc., Lifecare Neuro Products Ltd., Luye Pharma Group, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer, Inc., S. Karger AG, Seqirus Pty Ltd, Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries, Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Antipsychotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Class, market is studied across First Generation, Second Generation, and Third Generation. The First Generation is further studied across Haldo and Navane. The Second Generation is further studied across Geodon, Invega, Latuda, Risperdal, Seroquel, and Zyprexa. The Third Generation is further studied across Abilify.
• Based on Indication, market is studied across Bipolar Disorders, Dementia, Schizophrenia, and Unipolar Depression.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of psychosis and associated diseases
    • 5.1.1.2. Rising drug approval from governments
    • 5.1.1.3. Growing awareness regarding mental health and wellness
  • 5.1.2. Restraints
    • 5.1.2.1. Patent expiry of established brands
  • 5.1.3. Opportunities
    • 5.1.3.1. R&D and clinical trials for new antipsychotic drugs
    • 5.1.3.2. Improvements in antipsychotic drug testing
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory framework and compliance
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antipsychotic Drugs Market, by Class

• 6.1. Introduction
• 6.2. First Generation
  • 6.2.1. Haldo
  • 6.2.2. Navane
• 6.3. Second Generation
  • 6.3.1. Geodon
  • 6.3.2. Invega
  • 6.3.3. Latuda
  • 6.3.4. Risperdal
  • 6.3.5. Seroquel
  • 6.3.6. Zyprexa
• 6.4. Third Generation
  • 6.4.1. Abilify

7. Antipsychotic Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Bipolar Disorders
• 7.3. Dementia
• 7.4. Schizophrenia
• 7.5. Unipolar Depression

8. Americas Antipsychotic Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Antipsychotic Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Antipsychotic Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alkermes, Inc.
• 3. AMBOSS GmbH
• 4. Amgen Inc
• 5. Arlak Biotech
• 6. AstraZeneca PLC
• 7. Bristol-Myers Squibb Company
• 8. Daiichi Sankyo Company, Limited
• 9. Dr. Reddy's Laboratories, Ltd.
• 10. Eli Lilly and Company
• 11. Flagship Biotech International Pvt. Ltd.
• 12. GlaxoSmithKline PLC
• 13. H. Lundbeck A/S
• 14. Johnson & Johnson Services Inc.
• 15. Lifecare Neuro Products Ltd.
• 16. Luye Pharma Group
• 17. Merck & Co., Inc.
• 18. Novartis AG
• 19. Otsuka Pharmaceutical Co. Ltd.
• 20. Pfizer, Inc.
• 21. S. Karger AG
• 22. Seqirus Pty Ltd
• 23. Sumitomo Dainippon Pharma Co., Ltd.
• 24. Teva Pharmaceutical Industries, Ltd.
• 25. Vanda Pharmaceuticals Inc.